In the past, no-one would have considered social media as an essential part of patient engagement, let alone patient recruitment. However, Neil Weisman from Continuum Clinical explained during a session…
We were in sunny San Diego (not) at the 55th annual DIA meeting. The catchphrase this year is “connect and ascend” and there is a great emphasis on getting…
At a recent Summit in Miami, the emphasis for pharma, biotech and devices companies was overcoming the challenges of rare diseases.
ISPOR meetings are a great place for meeting old friends, making new acquaintances and finding out about the latest research in health economics and outcomes.
The annual ISPOR meeting held at Baltimore in May 2018 was no exception; however, from a medical communications agency’s perspective, there was one general observation – the standard of medical writing and presentation was appalling.
Predatory journals are scam publishers that charge authors fees upfront, but do not provide the service they promise. The majority of these predatory journals will take payments without ever publishing the work, while others publish articles without any form of an editorial or peer review process.
Chronic pain and other pain disorders are notoriously hard to treat, with approximately 40% of patients reporting insufficient relief from their medication. There is a huge unmet need for safe and effective drugs, referred to as analgesics, designed to treat pain as their primary function.
Recently, our company Rx communications Ltd has been involved in proposals for a number of literature review projects – one where an original review and analysis required updating before publication, and others that were designed to find answers to fairly obscure or unusual questions. We find, with the start of the year, many of our clients looking for vendors for these types of projects, and so we thought it might be useful to share our experiences.
Information is an important part of the patient journey and central to the overall quality of each patient’s experience with your drug, treatment or product. To help you get…
Regionalisation of phase IV trials because of payer differences sounds like a good thing in the short term. Improved market access, for one. But has anyone considered the longer term effects?
Interesting article in PharmaVoice in April 2012 – regarding Competitive Intelligence and Competitor Strategy. The article rightly points out that Pharma is leaving good intel on the table –by not…
